The VITA Project: Population-based distributions of Protein C, Antithrombin III, Heparin-cofactor II and plasminogen relationship with physiological variables and establishment of reference ranges

Thrombosis and Haemostasis

Volumn 76, Issue 2, 1996, Pages 226-233

  Rodeghiero, Francesco ^a   Tosetto, Alberto ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CHOLESTEROL; FIBRINOGEN; HEPARIN COFACTOR II; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PROTEIN C; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BLOOD GROUP; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COVARIANCE; DATA ANALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY CONTROL; REGRESSION ANALYSIS; SMOKING HABIT; STANDARD; THROMBOPHILIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029837881     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650559     Document Type: Article

References (45)

1. Mannucci PM, Tripodi A. Laboratory screening of inherited thrombotic syndromes. Thromb Haemost 1987; 57: 247-51.
2. Tosetto A, Frezzato M, Rodeghiero F. Family history and inherited thrombophilia. Br J Haematol 1995; 89: 227-8.
3. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-8.
4. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-80.
5. Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Wight M, Mitchell R, Davidson JF. Protein C activity in healthy volunteers. Influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1993; 70: 281-5.
6. Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Mitchell R, Davidson JF. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476-80.
7. Tait RC, Walker ID, Conkie JA, Islam SIAM, McCall F, Mitchell R, Davidson JF. Plasminogen levels in healthy volunteers. Influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1992; 68: 506-10.
8. Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994; 86: 798-803.
9. Rodeghiero F, Tosetto A. Some remarks on the epidemiology of thrombotic disorders. Thromb Haemost 1993; 69: 527-8.
10. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. Boston: PWS-Kent Publishing Company, 1988.
11. Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-4.
12. Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22.
13. Pabinger I, Brucker S, Kyrle PA, Schneider B, Korninger HC, Niessner H, Lechner K. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 1992; 3: 547-53.
14. Vikydal R, Korninger C, Kyrle PA, Niessner H, Pabinger I, Thaler E, Lechner K. The prevalence of hereditary antithrombin-III deficiency in patients with a history of venous thromboembolism. Thromb Haemost 1985; 54: 744-5.
15. Miletich J, Sherman L, Broze G, Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-6.
16. Frezzato M, Tosetto A, Rodeghiero F. Validation of a questionnaire for the diagnosis of previous venous thromboembolism. Br J Haematol 1994; 87 Suppl (1): 79.
17. Rose GA. The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bull WHO 1962; 27: 645-58.
18. The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) study: design and objectives. Am J Epidemiol 1989; 129: 687-702.
19. Rossi E, Mondonico P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res 1988; 52: 453-68.
20. Palareti G, Maccaferri M, Manotti C, Tripodi A, Chantarangkul V, Rodeghiero F, Ruggeri M, Mannucci PM, on behalf of C.I.S.M.E.L. Fibrinogen assays: a collaborative study of six different methods. Clin Chem 1991; 37: 714-9.
21. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8: 859-67.
22. Walker PA, Bauer KA, McDonagh J. A simple, automated functional assay for protein C. Am J Clin Pathol 1989; 92: 210-3.
23. Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with new chromogenic substrate (S2238 and Chromozyn TH). Thromb Res 1977; 11: 549-53.
24. Vinazzer H, Stocker K. Heparin cofactor II: experimental approach to a new assay and clinical results. Thromb Res 1991; 61: 235-41.
25. Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for the determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasia 1978; 7: 138-45.
26. Finney DJ. Statistical methods in biologic assay. London: C. Griffin, 1978.
27. Tosetto A, Gatto E, Masiero MT, Rodeghiero F. Parallel line bioassay or single-point calibration for the establishment of reference ranges. Thromb Res 1994; 75: 479-83.
28. Tosetto A, Rodeghiero F. Parallel line bioassay in coagulation laboratory. A program for personal computer use and an example application to ristocetin cofactor assay. Clin Lab Haematol 1991; 13: 371-7.
29. Hubbard AR. Standardization of protein C in plasma: establishment of an international standard. Thromb Haemost 1988; 59: 464-7.
30. Siedel J, Hagele EO, Ziegerhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-80.
31. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem 1952; 195: 357-66.
32. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379-88.
33. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-80.
34. Conlan MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sorlie P, Wu KK. Antithrombin III: association with age, race, sex and cardiovascular risk factors. Thromb Haemost 1994; 72: 551-6.
35. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 1993; 70: 762-7.
36. Daniel WW. Biostatistics: a foundation for analysis in the health sciences. New York: J. Wiley & Sons, 1987.
37. Solberg HE. Approved recommendation (1987) on the theory of reference values. Part 5. Determination of reference limits. J Clin Chem Clin Biochem 1987; 25: 645-56.
38. Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971; 17: 275-84.
39. Norusis MJ. SPSS/PC+ Statistics 4.0. Chicago: SPSS, Inc., 1990.
40. Solberg HE. Establishment and use of reference values. In: Fundamentals of Clinical Chemistry. Tietz NW, ed. W. B. Saunders Co., Philadelphia, 1987; pp 197-212.
41. Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alpha VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease. Br J Haematol 1985; 59: 249-58.
42. Tait RC, Walker ID, Islam SIAM, Mitchell R, Conkie JA, McCall F, Davidson JF. Age related changes in protein C activity in healthy adult males. Thromb Haemost 1991; 65: 326-7.
43. Mackie IJ, Segal H, Burren T, Gallimore M, Walsh KJ, Robinson G, Machin SJ. Heparin cofactor II levels are increased by the use of combined oral contraceptives. Blood Coagul Fibrinolysis 1990; 1: 647-51.
44. Massouh M, Jatoi A, Gordon EM, Ratnoff OD. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med 1989; 114: 697-9.
45. Andersson TR, Larsen ML, Handeland GF, Abildgaard U. Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population. Scand J Haematol 1986; 36: 96-102.